Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17169735 | 0.96 | TDP1 (0.45) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL13599217 | 0.92 | TDP1 (0.47) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL22856286 | 0.92 | TDP1 (0.47) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL17169723 | 0.92 | TDP1 (0.47) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL13599213 | 0.92 | TDP1 (0.47) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL23568359 | 0.92 | TDP1 (0.47) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL15112768 | 0.92 | TDP1 (0.50) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL17169717 | 0.91 | TDP1 (0.37) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL17169721 | 0.89 | CES2 (0.39) | TDP1KDM4EHSD17B10ALDH1A1NPC1 | |
| SCHEMBL22861714 | 0.89 | TDP1 (0.38) | TDP1KDM4EHSD17B10ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-11666581-B2 | PROTAC antibody conjugates and methods of use | GENENTECH, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | TDP1 4175/4885KDM4E 3738/4885HSD17B10 4250/4885 |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | TDP1 3884/4885KDM4E 570/4885HSD17B10 212/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | TDP1 2849/4885KDM4E 1613/4885HSD17B10 3818/4885 |
| US-20170008904-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | TDP1 1412/4885KDM4E 2212/4885HSD17B10 3330/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | TDP1 1896/4885KDM4E 498/4885HSD17B10 3884/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | TDP1 985/4885KDM4E 1450/4885HSD17B10 4294/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | TDP1 2059/4885KDM4E 676/4885HSD17B10 805/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | TDP1 3660/4885KDM4E 650/4885HSD17B10 232/4885 |
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | TBK1, TBKBP1, TNKS | TDP1 680/4885KDM4E 873/4885HSD17B10 3995/4885 |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | TDP1 1896/4885KDM4E 498/4885HSD17B10 3884/4885 |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | TDP1 361/4885KDM4E 2141/4885HSD17B10 836/4885 |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | TDP1 3568/4885KDM4E 1271/4885HSD17B10 2866/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | TDP1 561/4885KDM4E 2704/4885HSD17B10 3623/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | TDP1 2137/4885KDM4E 1205/4885HSD17B10 3204/4885 |
| US-11666581-B2 | PROTAC antibody conjugates and methods of use | PSMA3, PSMA6, PSMA2 | TDP1 4175/4885KDM4E 3738/4885HSD17B10 4250/4885 |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | TDP1 1228/4885KDM4E 2714/4885HSD17B10 2495/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | TDP1 2216/4885KDM4E 3016/4885HSD17B10 2792/4885 |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | GPER1, PSMA3, ESR2 | TDP1 4625/4885KDM4E 1169/4885HSD17B10 1922/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | TDP1 1896/4885KDM4E 498/4885HSD17B10 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.